Table 1.
Demographics of participants.
| Variables of interest | Herpes-zoster group(n = 192) | Control group(n = 28) | Old Herpes-zoster group(n = 27) | Control group(n = 14) |
|---|---|---|---|---|
| Age (years), (mean ± S.D.) | 57.69 ± 14.39 | 55.75 ± 9.78 | 67.74 ± 7.43 | 57.29 ± 5.08 |
| Sex (% female) | 48.96 | 53.57 | 44.44 | 42.86 |
| CRP(mg/l) | 11.43 ± 0.96▲▲ | 0.45 ± 0.05 | 14.91 ± 9.63▲▲ | 0.46 ± 0. 29 |
| WBC(109/l) | 5.66 ± 0.16 | 5.49 ± 0.31 | 6.28 ± 2.38 | 6.46 ± 2.22 |
| Neutrophil (%) | 60.81 ± 0.86 | 58.76 ± 1.02 | 62.88 ± 13.52 | 59.83 ± 15.68 |
| Neutrophil(109/l) | 3.59 ± 0.13▲▲ | 3.01 ± 0.16 | 4.34 ± 2.27 | 4.10 ± 2.19 |
| Lymphocyte (%) | 26.46 ± 0.78▲▲ | 30.61 ± 1.05 | 24.90 ± 10.03 | 27.15 ± 11.79 |
| Lymphocyte(109/l) | 1.54 ± 0.08 | 1.56 ± 0.13 | 1.45 ± 0.50 | 1.59 ± 0.50 |
| Monocyte (%) | 10.47 ± 0.32▲▲ | 8.09 ± 0.28 | 10.47 ± 4.96 | 11.46 ± 5.79 |
| Monocyte(109/l) | 0.59 ± 0.02 | 0.70 ± 0.11 | 0.62 ± 0.26 | 0.72 ± 0.26 |
| History of Herpes-zoster (whether they had been diagnosed at a medical institution) | no | no | no | no |
| History of Cytomegalovirus (whether they had been diagnosed at a medical institution) | no | no | no | no |
| History of Epstein Barr virus (whether they had been diagnosed at a medical institution) | no | no | no | no |
| History of Herpes simplex virus (whether they had been diagnosed at a medical institution) | no | no | no | no |
| Seroprevalence of Cytomegalovirus (%total group) | 55.21 | 53.57 | 56.37 | 54.37 |
| Seroprevalence of Epstein Barr virus (%total group) | 45.83 | 64.29 | 59.52 | 55.63 |
| Seroprevalence of Herpes Simplex virus 1 (%total group) | 39.06 | 35.71 | 44.44 | 42.86 |
| Seroprevalence of Herpes Simplex virus 2 (%total group) | 11.46 | 10.71 | 14.81 | 14.29 |
| Disease duration (days) | 3.02 ± 1.26 | NA | 2.86 ± 1.17 | NA |
| Postherpetic neuralgia (% at 4 weeks) | 46.35 | NA | 50.00 | NA |
NA: not applicable.
▲▲compare with the Control group P < 0.01.